Training With Whole Body Vibration Device in Patients With PAH (GALILEO-PAH)

March 30, 2015 updated by: Felix Gerhardt, Klinikum der Universität Köln

Influence of Training With Whole Body Vibration Device (Galileo) on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH). (GALILEO PAH)

Title of study / project: Influence of training with whole body vibration device on Quality of Life (QoL), exercise capacity, as well as on the effects of muscle power and muscle function in patients with pulmonal arterial hypertension (PAH). Background and rationale for the proposal:Capacity and the ability to exercise, in patients with PAH is limited. There is a few investigations evaluating the effects of the training with whole body vibration (wbv) in adults. It was shown that wbv-training could improve muscle power, QoL, body balance and had positive effects on the neuromuscular system. Primary scientific question addressed:Changes in muscle power, changes in 6-Minute Walk Distance (6MWD) and changes in QoL are to be evaluated.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Study Design: Open Monocentric prospective randomized observational trial Study arms: Treatment group (4-weeks wbv training) planned 20 patients Control group: planned 20 patients Endpoint (-s): Changes in muscle power, changes in 6-Minute Walk Distance (6MWD), changes in QoL changes in peak VO2 (bike exercise test)

Major study procedures:

Blood samples, vital parameters, questionnaires, echocardiography, lung function test, blood gas analysis, bike exercise test, 6-Minute Walk test, ECG, Chair rising test, power plate measurement, walk across test

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • NRW
      • Köln, NRW, Germany, 50937
        • Spezialambulanz für pulmonale Hypertonie Uniklinik Köln

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women age 18-90 years
  • Signed informed consent
  • Symptomatic PAH (idiopathic, hereditary or associated with systemic scleroderma)
  • Invasively confirmed PAH
  • 6MWT ≥ 50 m
  • Stable specific therapy for at least 2 months
  • Ability to perform bike test
  • Ability to perform wbv training
  • NYHA/WHO-FC II-III

Exclusion Criteria:

  • any other PAH/PH than idiopathic, hereditary or associated with systemic scleroderma
  • Rehabilitation or other training concept performed within 2 months before inclusion
  • pregnancy
  • acute thrombosis
  • newly implanted Hip or Knee
  • recent bone fracture
  • Disability to confirm consent
  • NYHA/WHO-FC IV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
This group will not do any specific training baseline and week 4 investigation will be done only
Active Comparator: Exercise Group Galileo PAH
The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
Device: Exercise Group Galileo PAH
The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
changes in 6-Minute Walk Distance (6MWD)
Time Frame: baseline and week 4
baseline and week 4

Secondary Outcome Measures

Outcome Measure
Time Frame
Changes in Quality of life
Time Frame: baseline and week 4
baseline and week 4
Changes in peak Vo2
Time Frame: baseline and week 4
baseline and week 4
Changes in muscle power
Time Frame: baseline and week 4
baseline and week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Klinikum der Universität Köln

Investigators

  • Principal Investigator: Felix Gerhardt, PhD, Klinik III für Innere Medizin Uniklinik Köln
  • Principal Investigator: Stephan Rosenkranz, PhD, Klinik III für Innere Medizin der Uniklinik Köln

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Anticipated)

June 1, 2015

Study Completion (Anticipated)

June 1, 2015

Study Registration Dates

First Submitted

January 4, 2013

First Submitted That Met QC Criteria

January 7, 2013

First Posted (Estimate)

January 8, 2013

Study Record Updates

Last Update Posted (Estimate)

March 31, 2015

Last Update Submitted That Met QC Criteria

March 30, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 001 (Buy Pharma Ecza Deposu San. Tic. Ltd.)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Artery Hypertension

Clinical Trials on Exercise Group Galileo PAH

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe